Raymond James Reiterates Outperform Rating, $24 Price Target on G1 Therapeutics (GTHX) Following Latest IQVIA Sales Data
Tweet Send to a Friend
Raymond James analyst Dane Leone reiterated an Outperform rating and $24.00 price target on G1 Therapeutics (NASDAQ: GTHX) on latest ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
